SCHEMBL1415792

SCHEMBL1415792

Fc1ccc(Oc2nccc(Cl)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.63
MAPT P10636 2/20 0.63
SCN9A Q15858 2/20 0.50
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
MAPK14 Q16539 3/20 0.41
TRPA1 O75762 2/20 0.40
S1PR2 O95136 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
HTT P42858 2/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
APAF1 O14727 1/20 0.39
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1414939 0.85 SCN9A (0.67) L3MBTL1MAPTSCN9AKCNH2SCN5A
SCHEMBL1415435 0.82 SCN9A (0.50) L3MBTL1MAPTSCN9AKCNH2SCN5A
SCHEMBL1415469 0.82 ALDH1A1 (0.57) L3MBTL1MAPTSCN9ACYP1A2CYP3A4
SCHEMBL10681003 0.82 MEN1 (0.61) L3MBTL1MAPTSCN9AKCNH2SCN5A
SCHEMBL9120208 0.81 SCN9A (0.49) L3MBTL1MAPTSCN9ACYP1A2CYP2C19
SCHEMBL5111507 0.80 SCN9A (0.44) L3MBTL1MAPTSCN9ACYP1A2CYP2C9
SCHEMBL1415443 0.79 SCN9A (0.47) L3MBTL1MAPTSCN9AMAPK14MEN1
SCHEMBL1415764 0.79 SCN9A (0.47) L3MBTL1MAPTSCN9AMEN1KMT2A
SCHEMBL1415358 0.79 MEN1 (0.50) L3MBTL1MAPTSCN9AMAPK14CYP1A2
SCHEMBL1415665 0.78 SMN1; SMN2 (0.49) L3MBTL1MAPTSCN9AMAPK14MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490360-B1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2011-03-16 EP disclosed
EP-1490360-A4 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2006-07-05 EP disclosed
EP-1490360-A1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2004-12-29 EP disclosed
US-6787551-B2 ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2004-09-07 US disclosed
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-06-24 US disclosed
WO-2003080605-A1 THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same GLP1R, PPARD, SLC5A1 L3MBTL1 4518/4885MAPT 2380/4885SCN9A 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.